Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 12, 2011 - Issue 13
Submit an article Journal homepage
464
Views
34
CrossRef citations to date
0
Altmetric
Reviews

An update expert opinion on management and research strategies in Parkinson's disease psychosis

Jennifer G GoldmanRush University Medical Center, Department of Neurological Sciences, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612 USA+1 312 563 2900; +1 312 563 2024; [email protected]
,
Christina L VaughanRush University Medical Center, Department of Neurological Sciences, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612 USA+1 312 563 2900; +1 312 563 2024; [email protected]
&
Christopher G GoetzRush University Medical Center, Department of Neurological Sciences, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612 USA+1 312 563 2900; +1 312 563 2024; [email protected]
Pages 2009-2024 | Published online: 02 Jun 2011

Citations (34)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Matthew J. Barrett, Leslie J. Cloud, Harsh Shah & Kathryn L. Holloway. (2020) Therapeutic approaches to cholinergic deficiency in Lewy body diseases. Expert Review of Neurotherapeutics 20:1, pages 41-53.
Read now
Han Zhang, Limin Wang, Yafei Fan, Lianhong Yang, Xiaojun Wen, Yunyun Liu & Zhonglin Liu. (2019) Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment 15, pages 2137-2149.
Read now
Yasaman Kianirad & Tanya Simuni. (2017) Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis. Expert Review of Clinical Pharmacology 10:11, pages 1161-1168.
Read now
Ines Chendo & Joaquim J Ferreira. (2016) Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy 17:15, pages 2115-2124.
Read now
Barbara S Connolly & Susan H Fox. (2012) Drug treatments for the neuropsychiatric complications of Parkinson’s disease. Expert Review of Neurotherapeutics 12:12, pages 1439-1449.
Read now

Articles from other publishers (29)

Dutta Rajib. (2023) Psychosis in Parkinson’s Disease and Current Management Trends- an Updated Review of Literature. Journal of Neuroscience and Neurological Disorders 7:2, pages 027-057.
Crossref
Nader R. Albujuq, J. Javier Meana, Rebeca Diez-Alarcia, Itziar Muneta-Arrate, Arshi Naqvi, Khalid Althumayri & Mosa Alsehli. (2023) Design, Synthesis, Molecular Docking, and Biological Evaluation of Novel Pimavanserin-Based Analogues as Potential Serotonin 5-HT 2A Receptor Inverse Agonists . Journal of Medicinal Chemistry 66:13, pages 9057-9075.
Crossref
P. Tall, M.A. Qamar, J. Chacko, K. Kee Leong, H. Al-Hashash, T. Marusich & K.R. Chaudhuri. 2023. Movement Disorders Emergencies. Movement Disorders Emergencies 1 15 .
Radomir Juza, Kamil Musilek, Eva Mezeiova, Ondrej Soukup & Jan Korabecny. (2022) Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders . Medicinal Research Reviews 43:1, pages 55-211.
Crossref
Milagros Rojas, Mervin Chávez-Castillo, Pablo Duran, Ángel Ortega, María Judith Bautista-Sandoval, Juan Salazar, Manuel Riaño-Garzón, Maricarmen Chacín, Oscar Medina-Ortiz, Jim Palmar, Lorena Cudris-Torres & Valmore Bermúdez. (2022) Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments. Current Pharmaceutical Design 28:33, pages 2725-2741.
Crossref
Iro Boura, Lucia Batzu, Espen Dietrichs & Kallol Ray Chaudhuri. 2022. Covid-19 and Parkinsonism. Covid-19 and Parkinsonism 135 171 .
Dalil Cherif Mghari. (2019) Mécanisme d’action de la pimavansérine : le nouvel antipsychotique pour traiter la psychose parkinsonienne. Annales Médico-psychologiques, revue psychiatrique 177:10, pages 1010-1012.
Crossref
Simon Loiodice, Harry Wing Young, Bertrand Rion, Benoît Méot, Pierre Montagne, Anne-Sophie Denibaud, Roselyne Viel & Christophe Drieu La Rochelle. (2019) Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson’s disease. Behavioural Brain Research 360, pages 120-127.
Crossref
Leslie Citrome. (2018) Psychiatric commentary addressing the article titled “Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus”. CNS Spectrums 23:6, pages 355-357.
Crossref
Jack J. Chen. (2017) Treatment of psychotic symptoms in patients with Parkinson disease. Mental Health Clinician 7:6, pages 262-270.
Crossref
R Lalonde & C Strazielle. (2017) A proposal for a semantic change in the current diagnostic criteria of Parkinson’s disease Psychosis. Open Journal of Parkinson's Disease and Treatment 1:1, pages 032-038.
Crossref
. (2016) Manage psychosis in Parkinson’s disease using a stepwise approach. Drugs & Therapy Perspectives 33:1, pages 16-21.
Crossref
Stephen M. Stahl. (2016) Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome. CNS Spectrums 21:5, pages 355-359.
Crossref
Stephen M. Stahl. (2016) Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors. CNS Spectrums 21:4, pages 271-275.
Crossref
Anna Chang & Susan H. Fox. (2016) Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management. Drugs 76:11, pages 1093-1118.
Crossref
R. Haussmann, M. Bauer & M. Donix. (2015) Evidenz zur Behandlung der Parkinson-assoziierten PsychoseEvidence-based treatment of psychosis associated with Parkinson’s disease. Der Nervenarzt 87:5, pages 543-551.
Crossref
I. de Chazeron, B. Pereira, I. Chereau-Boudet, G. Brousse, D. Misdrahi, G. Fénelon, A.-M. Tronche, R. Schwan, C. Lançon, A. Marques, B. Debilly, F. Durif & P.M. Llorca. (2015) Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease. Schizophrenia Research 161:2-3, pages 269-276.
Crossref
Ilia Bountouni, Panagiotis Zis, K. Ray Chaudhuri & Anette Schrag. 2015. Neuropsychiatric Symptoms of Movement Disorders. Neuropsychiatric Symptoms of Movement Disorders 113 139 .
Alexander Panickacheril John, Sitha Adriana, Julia Anne La’Brooy & Danuta Piepiorka-Sokolowska. (2014) Successful Treatment of Clozapine-Associated Restless Leg Syndrome With Pramipexole. Journal of Clinical Psychopharmacology 34:6, pages 764-766.
Crossref
F.I. Tarazi, Z.T. Sahli, M. Wolny & S.A. Mousa. (2014) Emerging therapies for Parkinson's disease: From bench to bedside. Pharmacology & Therapeutics 144:2, pages 123-133.
Crossref
Uli Hacksell, Ethan S. Burstein, Krista McFarland, Roger G. Mills & Hilde Williams. (2014) On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis. Neurochemical Research 39:10, pages 2008-2017.
Crossref
Nawaz Hack, Sarah M. Fayad, Erin H. Monari, Umer Akbar, Angela Hardwick, Ramon L. Rodriguez, Irene A. Malaty, Janet Romrell, Aparna A. Wagle. Shukla, Nikolaus McFarland, Herbert E. Ward & Michael S. Okun. (2014) An Eight-Year Clinic Experience with Clozapine Use in a Parkinson’s Disease Clinic Setting. PLoS ONE 9:3, pages e91545.
Crossref
Barbara Connolly & Susan H. Fox. (2013) Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease. Neurotherapeutics 11:1, pages 78-91.
Crossref
Kelly S.G. Aminian & Antonio P. Strafella. (2013) Affective disorders in Parkinsonʼs disease. Current Opinion in Neurology 26:4, pages 339-344.
Crossref
Thomas Knuijver, Indira Tendolkar, Rianne Esselink & Philip van Eijndhoven. (2013) Parkinson-psychose: een complex samenspel van ziekte- en medicatie-gerelateerde factoren. Tijdschrift voor Neuropsychiatrie en Gedragsneurologie 1:2, pages 45-50.
Crossref
Caroline Davis. (2013) From Passive Overeating to “Food Addiction”: A Spectrum of Compulsion and Severity. ISRN Obesity 2013, pages 1-20.
Crossref
Ross J. BaldessariniRoss J. Baldessarini. 2013. Chemotherapy in Psychiatry. Chemotherapy in Psychiatry 31 88 .
Joseph H Friedman. (2012) Management of psychotic symptoms in Parkinson’s disease. Clinical Practice 9:1, pages 49-55.
Crossref
Carina J. Bleickardt, Abigail L. LaShomb, Carrie E. Merkel & Robert A. Hodgson. (2012) Adenosine Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease. Parkinson's Disease 2012, pages 1-9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.